What is HC Wainwright’s Estimate for Prothena Q4 Earnings?

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at HC Wainwright issued their Q4 2025 EPS estimates for Prothena in a research note issued to investors on Friday, February 21st. HC Wainwright analyst A. Fein expects that the biotechnology company will post earnings per share of ($0.58) for the quarter. HC Wainwright currently has a “Buy” rating and a $48.00 target price on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

PRTA has been the subject of a number of other reports. StockNews.com lowered shares of Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. Bank of America cut their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. Chardan Capital reissued a “buy” rating and set a $40.00 price objective on shares of Prothena in a research report on Friday. Oppenheimer boosted their price objective on shares of Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a research report on Friday, February 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a research report on Friday. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Prothena presently has an average rating of “Moderate Buy” and a consensus price target of $45.83.

Prothena Stock Up 2.0 %

Shares of NASDAQ PRTA opened at $15.56 on Monday. Prothena has a twelve month low of $11.70 and a twelve month high of $31.03. The firm has a market cap of $837.27 million, a P/E ratio of -6.77 and a beta of 0.08. The company has a 50 day moving average of $14.33 and a 200 day moving average of $16.76.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.12 million during the quarter, compared to analysts’ expectations of $7.53 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PRTA. Wellington Management Group LLP boosted its holdings in Prothena by 22.8% in the 4th quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company’s stock worth $71,063,000 after buying an additional 952,088 shares during the period. Boxer Capital Management LLC bought a new position in Prothena in the 4th quarter worth $9,556,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Prothena by 1,122.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock worth $8,812,000 after buying an additional 483,673 shares during the period. Federated Hermes Inc. boosted its holdings in Prothena by 84.3% in the 4th quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company’s stock worth $10,335,000 after buying an additional 341,274 shares during the period. Finally, Finepoint Capital LP boosted its holdings in Prothena by 51.6% in the 4th quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company’s stock worth $9,100,000 after buying an additional 223,600 shares during the period. Institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.